{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:30:08Z","timestamp":1778128208288,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd014384","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000}}],"reference-count":310,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014384.pub2","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T04:22:41Z","timestamp":1669263761000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antipsychotic dose reduction compared to dose continuation for people with schizophrenia"],"prefix":"10.1002","volume":"2022","author":[{"given":"Alessandro","family":"Rodolico","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Psychiatry Unit; University of Catania; Catania Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0 and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0 and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrto T","family":"Samara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine; University of Thessaly; Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wulf-Peter","family":"Hansen","sequence":"additional","affiliation":[{"name":"BASTA - B\u00fcndnis f\u00fcr psychisch erkrankte Menschen; M\u00fcnchen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Salomone","sequence":"additional","affiliation":[{"name":"Biomedical and Biotechnological Sciences; University of Catania; Catania Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Aguglia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Psychiatry Unit; University of Catania; Catania Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfelice","family":"Cutrufelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Psychiatry Unit; University of Catania; Catania Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Bauer","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0 and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"},{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty; University of Augsburg; Augsburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lio","family":"Baeckers","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0 and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Section for Evidence Based Medicine in Psychiatry\u00a0 and Psychotherapy, Department of Psychiatry and Psychotherapy, School of Medicine; Technical University of Munich; Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0001|cit1","first-page":"118","article-title":"Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia","volume":"17","author":"Branchey","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1176\/ajp.138.5.608","article-title":"Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia \u00a0in schizophrenic patients","volume":"138","author":"Branchey","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1176\/ajp.120.6.578","article-title":"Phenothiazine excretion in chronic schizophrenics","volume":"120","author":"Caffey","year":"1963","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0021-9681(64)90075-x","article-title":"Discontinuation or reduction of chemotherapy in chronic schizophrenics","volume":"17","author":"Diamond","year":"1964","journal-title":"Journal of Chronic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1176\/ajp.156.3.412","article-title":"Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks","volume":"156","author":"Buchanan","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00004850-198704000-00008","article-title":"The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime","volume":"2","author":"Cookson","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD014384.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1176\/ps.40.11.1193","article-title":"Neuroleptic dose reduction in persistently psychotic patients","volume":"40","author":"Faraone","year":"1989","journal-title":"Hospital and Community Psychiatry"},{"issue":"S1","key":"10.1002\/14651858.CD014384.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1016\/S0920-9964(14)70830-8","article-title":"The effect of previous dose or oral aripiprazole (10 or 30 mg\/day) on the efficacy and tolerability of aripiprazole once-monthly: results from post-hoc analyses from two double-blind randomized controlled trials","volume":"153","author":"Baker","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1016\/S0924-977X(14)70866-1","article-title":"P.3.d.033 The effects of aripiprazole once-monthly on the PANSS Marder factors in the treatment of patients with schizophrenia","volume":"24","author":"Baker","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/NDT.S80479","article-title":"Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis","volume":"11","author":"De Hert","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0011|cit11","first-page":"69","article-title":"The efficacy and safety of aripiprazole once-monthly in obese and non-obese patients with schizophrenia; a post-hoc analysis","volume":"17","author":"Eramo","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1016\/S0924-9338(14)78135-0","article-title":"All-cause discontinuation and safety of aripiprazole once-monthly for the treatment of schizophrenia: a pooled analysis of two double-blind, randomized, controlled trials","volume":"29","author":"Eramo","year":"2014","journal-title":"European Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD014384.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.schres.2014.09.019","article-title":"Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies","volume":"159","author":"Fleischhacker","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"S474","DOI":"10.1016\/S0924-977X(13)70751-X","article-title":"P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole","volume":"23","author":"Fleischhacker","year":"2013","journal-title":"European Neuropsychopharmacology"},{"issue":"Poster Session","key":"10.1002\/14651858.CD014384.pub2-BIB0015|cit15","first-page":"S394","article-title":"Safety and effectiveness of aripiprazole once-monthly for the treatment of schizophrenia: a pooled analysis of two double-blind, randomized, controlled trials (246 and 247)","volume":"38","author":"Fleischhacker","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1038\/npp.2012.221","article-title":"Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole","volume":"38","author":"Fleischhacker","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1192\/bjp.bp.113.134213","article-title":"Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study","volume":"205","author":"Fleischhacker","year":"2014","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0018|cit18","unstructured":"Holtzhausen A A 38 \u00adweek, multicenter, randomized, double\u00adblind, active\u00ad controlled study to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole (OPC\u00ad 14597) as maintenance treatment in patients with schizophrenia \u201cASPIRE EU\u201d (Aripiprazole Intramuscular Depot Program in Schizophrenia) South African National Clinical Trial Register 2008"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3371\/CSRP.KASA.022015","article-title":"Patient-centered outcomes with aripiprazole once-monthly for maintenance treatment in patients with schizophrenia: results from two multicenter, randomized, double-blind studies","volume":"9","author":"Kane","year":"2015","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0020|cit20","unstructured":"Intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia (ASPIRE) clinicaltrials.gov\/ct2\/show\/NCT00706654"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1017\/S1461145714000741","article-title":"The effect of previous dose of oral aripiprazole (10 or 30 mg\/day) on the efficacy and tolerability of aripiprazoleonce-monthly: post-hoc analysis of two double-blind, randomized, controlled trials","volume":"17","author":"Nylander","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0022|cit22","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc Clinical Summary for Protocol 31-07-247NCT No. 00706654 clinical-trials.otsuka.com\/sites\/g\/files\/qhldwo4256\/files\/2020-05\/31-07-247%20Clinical%20Summary.pdf"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S473","DOI":"10.1016\/S0924-977X(13)70750-8","article-title":"P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole","volume":"23","author":"Peters-Strickland","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0024|cit24","unstructured":"Hirschowitz J Hitzemann R Curtis C Piscani K Dose reduction in schizophrenia 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995 Dec 11-15; San Juan, Puerto Rico 1995 166"},{"issue":"9","key":"10.1002\/14651858.CD014384.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/archpsyc.1988.01800330021002","article-title":"Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study","volume":"45","author":"Hogarty","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archpsyc.1995.03950130029004","article-title":"Pharmacotherapy of impaired affect in recovering schizophrenic patients","volume":"52","author":"Hogarty","year":"1995","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0027|cit27","unstructured":"Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-000338-37\/DE"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00406-020-01109-y","article-title":"Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial","volume":"271","author":"Huhn","year":"2020","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0029|cit29","unstructured":"Evaluation of the necessity of long-term pharmacological treatment with antipsychotics in schizophrenic patients clinicaltrials.gov\/ct2\/show\/NCT02307396"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1192\/bjp.151.5.634","article-title":"Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia","volume":"151","author":"Johnson","year":"1987","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0031|cit31","first-page":"533","article-title":"High-dose versus low-dose strategies in the treatment of schizophrenia","volume":"21","author":"Kane","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD014384.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/archpsyc.1983.01790070083010","article-title":"Low-dose neuroleptic treatment of outpatient schizophrenics: i. Preliminary results for relapse rates","volume":"40","author":"Kane","year":"1983","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0033|cit33","first-page":"20","article-title":"Low-dose neuroleptics in outpatient schizophrenics","volume":"18","author":"Kane","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167","author":"Kane","year":"2010","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0035|cit35","unstructured":"A double-blind, randomized study comparing intramuscular olanzapine depot to oral olanzapine and low-dose depot in the maintenance therapy of patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00088491"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0036|cit36","unstructured":"Comparison of intramuscular olanzapine depot to oral olanzapine and low dose depot in patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00088491"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1023\/A:1009520106119","article-title":"Decreasing neuroleptic doses in older adults with schizophrenia","volume":"6","author":"Kinion","year":"2000","journal-title":"Journal of Clinical Geropsychology"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1600-0447.1978.tb06877.x","article-title":"Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study","volume":"57","author":"Lonowski","year":"1978","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0165-1781(92)90001-J","article-title":"Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease","volume":"28","author":"Newcomer","year":"1992","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/jcp.0000000000001046","article-title":"Model-guided antipsychotic dose reduction in schizophrenia: a pilot, single-blind randomized controlled trial","volume":"39","author":"Ozawa","year":"2019","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0041|cit41","unstructured":"Model-guided antipsychotic dose reduction in schizophrenia: a single-blind randomized controlled trial rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000014976"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0042|cit42","unstructured":"Antipsychotic medication extended dosing study clinicaltrials.gov\/ct2\/show\/NCT00431574"},{"issue":"8","key":"10.1002\/14651858.CD014384.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.4088\/jcp.09m05866yel","article-title":"\"Extended\" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial","volume":"72","author":"Remington","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD014384.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.euroneuro.2008.04.012","article-title":"Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study","volume":"18","author":"Rouillon","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archpsyc.1997.01830170079011","article-title":"Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment","volume":"54","author":"Schooler","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD014384.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.4088\/jcp.13m08841","article-title":"Dose reduction of risperidone and olanzapine and estimated dopamine D(2) receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study","volume":"75","author":"Takeuchi","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"S385","DOI":"10.1002\/central\/CN-01040905\/","article-title":"Impact of atypical antipsychotic dose reduction on cognitive function and subjective experiences","volume":"39","author":"Takeuchi","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/schbul\/sbt090","article-title":"Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study","volume":"39","author":"Takeuchi","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/JCP.0000000000000142","article-title":"Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia","volume":"34","author":"Takeuchi","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD014384.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.psychres.2014.04.019","article-title":"Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia","volume":"218","author":"Takeuchi","year":"2014","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.1093\/schbul\/sbt011","article-title":"Effects of atypical antipsychotic dose reduction on cognitive function in stable patients with schizophrenia: a randomized controlled trial","volume":"39","author":"Takeuchi","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD014384.pub2-BIB0052|cit52","first-page":"562","article-title":"Optimal antipsychotic dose and dosing interval in the treatment of schizophrenia","volume":"117","author":"Takeuchi","year":"2015","journal-title":"Psychiatria et neurologia Japonica"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0053|cit53","unstructured":"Effects of antipsychotic reduction on negative subjective experience and cognitive function rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000001834"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/00004714-200004000-00020","article-title":"High dose treatment with haloperidol: the effect of dose reduction","volume":"20","author":"Volavka","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0055|cit55","unstructured":"Volavka J Cooper TB Czobor P Lindenmayer JP Citrome LL Mohr P Haloperidol blood levels and effects in schizophrenia 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA 1997"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12888-016-1103-3","article-title":"Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia","volume":"16","author":"Bo","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JCP.0000000000000464","article-title":"Extrapyramidal symptoms during risperidone maintenance treatment in schizophrenia: a prospective, multicenter study","volume":"36","author":"Bo","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0058|cit58","unstructured":"Risperidone maintenance treatment in schizophrenia clinicaltrials.gov\/ct2\/show\/NCT00848432"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1176\/appi.ajp.2009.09030358","article-title":"Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial","volume":"167","author":"Wang","year":"2010","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD014384.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1176\/appi.ajp.2010.10030409r","article-title":"Reply to Uchida et al","volume":"167","author":"Wang","year":"2010","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD014384.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00127-010-0304-1","article-title":"Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study","volume":"46","author":"Xiang","year":"2011","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1744-6163.2010.00281.x","article-title":"Socio-demographic and clinical profiles of paranoid and nonparanoid schizophrenia: a prospective, multicenter study in China","volume":"47","author":"Xiang","year":"2011","journal-title":"Perspectives in Psychiatric Care"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0031-1277178","article-title":"Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia","volume":"44","author":"Xiang","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.psychres.2010.03.014","article-title":"Sex differences in patients with schizophrenia: a prospective, multi-center study","volume":"177","author":"Xiang","year":"2010","journal-title":"Psychiatry Research"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4088\/JCP.11m07069","article-title":"Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial","volume":"73","author":"Faber","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0066|cit66","unstructured":"Medication strategies in first onset schizophrenia (Mesifos) www.isrctn.com\/ISRCTN16228411"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0067|cit67","unstructured":"Medication strategies in first onset schizophrenia (MESIFOS) www.isrctn.com\/ISRCTN16228411"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0920-9964(03)80502-9","article-title":"MESIFOS: Medication strategies in first onset schizophrenia effects of short versus sustained antipsychotic treatment on quality of life after first episode psychosis: a randomized trial","volume":"60","author":"Nienhuis","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0069|cit69","first-page":"498","article-title":"Feasibility of carrying out maintenance or targeted medication treatment in first onset schizophrenia: the MESIFOS RCT","volume":"31","author":"Nienhuis","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0920-9964(06)70151-7","article-title":"Feasibility of carrying out targeted and maintenance treatment in first episode psychosis","volume":"86","author":"Nienhuis","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0071|cit71","first-page":"450","article-title":"Feasibility of targeted and maintenance treatment in remitted first episode psychosis","volume":"33","author":"Nienhuis","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0920-9964(06)70152-9","article-title":"Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome","volume":"86","author":"Wunderink","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0073|cit73","unstructured":"Wunderink A Wiersma D de Wit P Outcome of two medication strategies in first-onset schizophrenia: the MESIFOS RCT 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA 2005 Nr214"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(14)70215-4","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy","volume":"153","author":"Wunderink","year":"2014","journal-title":"Schizophrenia Research"},{"issue":"9","key":"10.1002\/14651858.CD014384.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD014384.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19.","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(14)70215-4","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy","volume":"153","author":"Wunderink","year":"2014","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0078|cit78","first-page":"S358","article-title":"Recovery in remitted first episode psychosis at 7 years of follow-up of early guided discontinuation or maintenance treatment","volume":"39","author":"Wunderink","year":"2013","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0079|cit79","first-page":"S358","article-title":"Recovery in remitted first episode psychosis at 7 years of follow-up of early guided discontinuation or maintenance treatment","volume":"39","author":"Wunderink","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0080|cit80","first-page":"A57","article-title":"Guided discontinuation trial versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome","volume":"2","author":"Wunderink","year":"2008","journal-title":"Early Intervention in Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0081|cit81","first-page":"466","article-title":"Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome","volume":"33","author":"Wunderink","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"654","DOI":"10.4088\/jcp.v68n0502","article-title":"Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome","volume":"68","author":"Wunderink","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0920-9964(03)80238-4","article-title":"Medication strategies in first onset schizophrenia: a randomized trial of effectiveness of short versus sustained antipsychotic treatment and quality of life in first episode psychosis preliminary findings: incidence, compliance and early course","volume":"60","author":"Wunderink","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0084|cit84","unstructured":"Wunderink L Sytema S Wiersma D Discontinuation challenge in remitted first episode psychosis: relapse rates and functional outcome compared with maintenance treatment 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain 2009"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.schres.2019.12.001","article-title":"Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy","volume":"216","author":"Wunderink","year":"2020","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0086|cit86","unstructured":"Follow-up study of the risk of relapse and the function after reducing high doses risperidone maintenance treatment in patient with schizophrenia apps.who.int\/trialsearch\/Trial.aspx?TrialID=ChiCTR-POC-15006642"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/0269881118756062","article-title":"Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study","volume":"32","author":"Zhou","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0089|cit89","unstructured":"RAPID - an open-label, randomised, multicentre phase IIIb study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia \/ schizoaffective disorder (rapid versus conventional titration) clinicaltrials.gov\/ct2\/show\/NCT00803101"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0920-9964(01)00381-4","article-title":"Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation","volume":"53","author":"Baker","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0920-9964(03)80427-9","article-title":"Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation\u00a0","volume":"60","author":"Baker","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/01.jcp.0000085406.08426.a8","article-title":"Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation","volume":"23","author":"Baker","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0093|cit93","unstructured":"A double blind study to compare the switch of long-stay stabilized patients with schizophrenia or schizoaffective disorder to ziprasidone with low-dose conventional antipsychotics; followed by an open, prospective study to compare ziprasidone to clozapine www.trialregister.nl\/trial\/5711"},{"issue":"9","key":"10.1002\/14651858.CD014384.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.euroneuro.2018.06.005","article-title":"Dose reduction of high-dose \ufb01rst-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial","volume":"28","author":"Bogers","year":"2018","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1093\/schbul\/sby017.584","article-title":"Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: a 1-year double-blind randomized clinical trial","volume":"44 (S1)","author":"Bogers","year":"2018","journal-title":"Abstracts for the Sixth Biennial SIRS Conference"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0096|cit96","unstructured":"Caffey EM An evaluation of the treatment of drug-induced extrapyramidal symptoms 5th World Congress of Psychiatry; 1971 Nov 28-Dec 4; Mexico City 1971 225 6"},{"issue":"12","key":"10.1002\/14651858.CD014384.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1176\/ps.48.12.1571","article-title":"Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia","volume":"48","author":"Dellva","year":"1997","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.2147\/NDT.S130211","article-title":"Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study","volume":"13","author":"Durgam","year":"2017","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0099|cit99","unstructured":"A fixed-dose range safety and efficacy study of olanzapine versus haloperidol in the treatment of schizophrenia assets.ctfassets.net\/hadumfdtzsru\/1GdsS40cIYEEqyUOWKGmsi\/a23a6fa3d5560dc1d34683661bcfe29a\/Olanzapine-F1D-EW-E003.pdf"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0100|cit100","unstructured":"Olanzapine versus placebo and haloperidol in the treatment of schizophrenia assets.ctfassets.net\/hadumfdtzsru\/1vEkFeR3isUCwQeMi2MyOi\/7286a8a03eb6520dd610750d9ba92b66\/Olanzapine-F1D-MC-HGAD.pdf"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0101|cit101","unstructured":"European Medicines Agency Abilify H-C-471; European Public Assessment Report; Scientific discussion www.ema.europa.eu\/en\/documents\/scientific-discussion\/abilify-epar-scientific-discussion_en.pdf"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4088\/JCP.11m07069","article-title":"Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial","volume":"73","author":"Faber","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD014384.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"1169\u201377","DOI":"10.1001\/archpsyc.1978.01770340019001","article-title":"Drug and family therapy in the aftercare of acute schizophrenics","volume":"35","author":"Goldstein","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD014384.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0920-9964(97)00083-2","article-title":"Neuroleptic dose reduction in older psychotic patients","volume":"27","author":"Harris","year":"1997","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0105|cit105","unstructured":"Harris MJ Paulsen JS Rockwell E Jeste DV Neuroleptic maintenance treatment in the elderly 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA 1997"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0920-9964(96)00074-6","article-title":"The dose reduction in schizophrenia (DORIS) study: a final report","volume":"23","author":"Hirschowitz","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD014384.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.kjms.2011.06.014","article-title":"Rapid initiation of quetiapine well tolerated as compared with the conventional initiation regimen in patients with schizophrenia or schizoaffective disorders","volume":"27","author":"Hsiao","year":"2011","journal-title":"Kaohsiung Journal of Medical Sciences"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1176\/ps.47.1.83","article-title":"Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics","volume":"47","author":"Huttunen","year":"1996","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0920-9964(93)90531-M","article-title":"Most effective dose study (meds): a double-blind reduction trial of fluphenazine decanoate","volume":"9","author":"Inderbitzin","year":"1993","journal-title":"Schizophrenia Research"},{"issue":"12","key":"10.1002\/14651858.CD014384.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1176\/ajp.151.12.1753","article-title":"A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients","volume":"151","author":"Inderbitzin","year":"1994","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0111|cit111","first-page":"27","article-title":"Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results","volume":"20","author":"Kalachnik","year":"1984","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"341\u20138","DOI":"10.1016\/0165-1781(79)90016-7","article-title":"Low dose fluphenazine decanoate in maintenance treatment of schizophrenia","volume":"1","author":"Kane","year":"1979","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1176\/appi.ajp.159.4.554","article-title":"A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia","volume":"159","author":"Kane","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0114|cit114","first-page":"109","article-title":"Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate","volume":"8","author":"Khazaie","year":"2005","journal-title":"Archives of Iranian Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0115|cit115","first-page":"S165","article-title":"Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study","volume":"5","author":"Kinon","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.pnpbp.2004.05.016","article-title":"Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods","volume":"28","author":"Kinon","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0117|cit117","unstructured":"Kinon BJ Stauffer VL Wang L Thi KT Olanzapine improves tardive dyskinesia in patients with schizophrenia 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia 2002"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0118|cit118","first-page":"191","article-title":"Olanzapine improves tardive dyskinesia in patients with schizophrenia","volume":"53","author":"Kinon","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Kollack-Walker S Kinon BJ Stauffer VL Wang L Thi KT Olanzapine improves tardive dyskinesia in patients with schizophrenia Abstracts of the IXth International Congress on Schizophrenia Research; 2003 Mar 29-Apr 2; Colorado Springs, Colorado 2003","DOI":"10.1016\/S0920-9964(03)80175-5"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"S359","DOI":"10.1016\/S0920-9964(03)80175-5","article-title":"Olanzapine improves tardive dyskinesia in patients with schizophrenia","volume":"60","author":"Kollack-Walker","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0121|cit121","first-page":"79","article-title":"Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia","volume":"11","author":"Koshikawa","year":"1991","journal-title":"Yakubutsu Seishin Kodo [Japanese Journal of Psychopharmacology]"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","article-title":"The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial","volume":"114","author":"Lecrubier","year":"2006\u00a0","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0123|cit123","first-page":"S162","article-title":"Effective titration of risperidone in Korean patients with schizophrenia: open multicenter randomized comparative study","volume":"3","author":"Lee","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0124|cit124","first-page":"276","article-title":"Effective titration of risperidone in patients with schizophrenia: open multicenter randomized comparative 8 weeks study","volume":"13","author":"Lee","year":"2002","journal-title":"Korean Journal of Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/0924-977x(91)90008-i","article-title":"Zuclopenthixol, a combined dopamine D1\/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia","volume":"1","author":"Lublin","year":"1991","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"281\u20138","DOI":"10.1016\/j.schres.2013.06.041","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study","volume":"150","author":"Mallikaarjun","year":"2013","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD014384.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/archpsyc.1983.01790220015002","article-title":"Costs and benefits of two doses of fluphenazine","volume":"41","author":"Marder","year":"1984","journal-title":"Archives of General Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD014384.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1177\/106002809402801002","article-title":"Preliminary comparison of predictive and empiric lithium dosing: impact on patient outcome","volume":"28","author":"Marken","year":"1994","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Matkovits-Gupta T Lasser R Young F Happy J Gharabawi G Cucchiaro J Managing psychotic disorders through balanced receptor blockade: the Zomaril\u2122 clinical program; 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999","DOI":"10.2165\/00128413-199912110-00012"},{"issue":"1-2 Suppl","key":"10.1002\/14651858.CD014384.pub2-BIB0130|cit130","first-page":"238","article-title":"Safety and efficacy of iloperidone in patients with psychotic disorders: a randomized, double-blind multicenter study","volume":"49","author":"Matkovits-Gupta","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/s0033-3182(65)72252-4","article-title":"Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines","volume":"6","author":"Miller","year":"1965","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0132|cit132","unstructured":"Rapid dose escalation of quetiapine versus conventional escalation in the treatment of patients with acute schizophrenia a multicentre, double-blind, parallel group, randomized study clinicaltrials.gov\/ct2\/show\/NCT00254787"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0133|cit133","unstructured":"Fast titration of quetiapine versus currently approved titration: a randomised, multicentre, parallel group open trial in schizophrenia and schizoaffective disorder clinicaltrials.gov\/ct2\/show\/NCT00254813"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0134|cit134","unstructured":"Fast titration of quetiapine versus conventional titration in the treatment of schizophrenia\/schizoaffective disorder - a randomised, parallel group open trial clinicaltrials.gov\/ct2\/show\/NCT00304473"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0135|cit135","unstructured":"RAPID - an open-label randomized, multicenter phase iiib study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia\/schizoaffective disorder (rapid versus conventional titration) clinicaltrials.gov\/ct2\/show\/NCT00457899"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0136|cit136","unstructured":"FAST - a study to evaluate the efficacy and safety of quetiapine IR in patients with acute psychosis clinicaltrials.gov\/ct2\/show\/NCT00486798"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0137|cit137","unstructured":"Evaluate the pharmacokinetics of quetiapine fumarate in Chinese schizophrenic patients clinicaltrials.gov\/ct2\/show\/NCT00919607"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00427763","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine","volume":"82","author":"Nishikawa","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD014384.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/0006-3223(85)90174-x","article-title":"Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers","volume":"20","author":"Nishikawa","year":"1985","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD014384.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/0006-3223(89)90265-5","article-title":"Prophylactic effects of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of timiperone and sulpiride","volume":"25","author":"Nishikawa","year":"1989","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4088\/jcp.v68n0307","article-title":"Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial","volume":"68","author":"Pae","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014384.pub2-BIB0142|cit142","first-page":"S505","article-title":"Rapid versus conventional titration of quetiapine in acute schizophrenia","volume":"15","author":"Pae","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0143|cit143","unstructured":"Pae CU Kim TS Kim JJ Lee SJ Lee CU Paik IH Rapid versus conventional initiation of quetiapine in acute schizophrenia 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0144|cit144","first-page":"94","article-title":"Fast dosage of quetiapine in comparison to conventional dosage in the treatment of acute schizophrenic patients - a multi-central double-blind randomised study","volume":"78","author":"Schultz","year":"2007","journal-title":"Nervenarzt"},{"issue":"8","key":"10.1002\/14651858.CD014384.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.4088\/jcp.v67n0804","article-title":"A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0146|cit146","unstructured":"Smith MA McCoy R Hamer J Brecher M Optimal titration for quetiapine: pilot trial; NCDEU Annual Meeting; 2002 Jun 10-13; Boca Raton, Florida 2002"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0147|cit147","first-page":"21","article-title":"The effect of neuroleptic medication on behaviour in chronic schizophrenia","volume":"15","author":"Soria","year":"1994","journal-title":"Psiquis"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/00004714-199710000-00011","article-title":"Two rapid-dose titrations of sertindole in patients with schizophrenia","volume":"17","author":"Sramek","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0149|cit149","first-page":"811","article-title":"A bridging study of fananserin in schizophrenic patients","volume":"34","author":"Sramek","year":"1998","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0150|cit150","first-page":"169","article-title":"A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics","volume":"1","author":"Sukegawa","year":"2008","journal-title":"Tottori Journal of Clinical Research"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0151|cit151","first-page":"712","article-title":"Implementation of appropriate administration of antipsychotics - measures to reduce high-dose multiple antipsychotics","volume":"71","author":"Sukegawa","year":"2013","journal-title":"Nihon Rinsho [Japanese Journal of Clinical Medicine]"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0152|cit152","first-page":"696","article-title":"Measures to reduce high-dose multiple antipsychotics in Japan","volume":"114","author":"Sukegawa","year":"2012","journal-title":"Seishin Shinkeigaku Zasshi [Psychiatria et Neurologia Japonica]"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0006-3223(92)90229-S","article-title":"Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically medicated schizophrenia","volume":"31","author":"Suzuki","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/01.jcp.0000106226.36344.83","article-title":"Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?","volume":"24","author":"Townsend","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/01.jcp.0000195384.04008.25","article-title":"Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect","volume":"26","author":"Uchida","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0920-9964(01)00268-7","article-title":"Does cognitive function improve with quetiapine in comparison to haloperidol?","volume":"53","author":"Velligan","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0157|cit157","unstructured":"The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000005391"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-244X-14-103","article-title":"Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan","volume":"14","author":"Sukegawa","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ijnp\/pyu016","article-title":"Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method","volume":"18","author":"Yamanouchi","year":"2015","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"288\u201394","DOI":"10.1097\/WNF.0000000000000175","article-title":"Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study","volume":"39","author":"Yoon","year":"2016","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13063-019-3822-5","article-title":"To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction\/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial","volume":"21","author":"Begemann","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0162|cit162","unstructured":"HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A pragmatic single blind RCT of continuation versus discontinuation\/dose reduction of antipsychotic medication in patients remitted after a first episode of psychosis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-002406-12-NL"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.1093\/schbul\/sbaa029.598","article-title":"T38. Poster presentation: HAMLETT: Handling antipsychotic medication, a longterm evaluation of targeted treatment a pragmatic single-blind randomised controlled trial of continuation versus discontinuation of psychotic medication","volume":"46","author":"van\u2018t Hag","year":"2020","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0164|cit164","unstructured":"Dose reduction of long-acting injectable second-generation antipsychotics in stable schizophrenia: a multicenter, double-blind, randomized controlled trial center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000042506"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0165|cit165","first-page":"S414","article-title":"A proposed alternative between discontinuation and maintenance of antipsychotics: a guided dose reduction trial for patients with remitted psychosis","volume":"44 (S1)","author":"Liu","year":"2018","journal-title":"Abstracts for the Sixth Biennial SIRS Conference"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0166|cit166","unstructured":"Research Into Antipsychotic Discontinuation and Reduction (RADAR) clinicaltrials.gov\/ct2\/show\/NCT03559426"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0167|cit167","unstructured":"A clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in patients with schizophrenia trialsearch.who.int\/Trial2.aspx?TrialID=NCT03593213"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0168|cit168","unstructured":"Clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in patients with schizophrenia clinicaltrials.gov\/ct2\/show\/NCT03593213"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0169|cit169","unstructured":"Does antipsychotic dose reduction in combination with Evidence-Based Intensive Recovery Treatment (EBIRT) lead to better functional recovery in first episode psychosis: a randomised controlled trial www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12617000870358"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/eip.12769","article-title":"Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: study protocol","volume":"13","author":"Weller","year":"2019","journal-title":"Early Intervention in Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/eip.12724","article-title":"Less is more? An Australian RCT comparing dose reduction of anti-psychotic medication to maintenance treatment","volume":"12","author":"Weller","year":"2018","journal-title":"Early Intervention in Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12888-018-1856-y","article-title":"Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia","volume":"18","author":"Achtyes","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"S22","key":"10.1002\/14651858.CD014384.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"163","author":"Addington","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0174|cit174","first-page":"159","article-title":"The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia","volume":"25","author":"Alphs","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF02190085","article-title":"Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics","volume":"240","author":"Altamura","year":"1990","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"7066","key":"10.1002\/14651858.CD014384.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"62","author":"Andreasen","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","article-title":"Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study","volume":"170","author":"Andreasen","year":"2013","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0179|cit179","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)","author":"American Psychiatric Association","year":"1987"},{"issue":"1-2","key":"10.1002\/14651858.CD014384.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0920-9964(02)00355-9","article-title":"Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL","volume":"63","author":"Auquier","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/19.3.609","article-title":"Subjective response to neuroleptics in schizophrenia","volume":"19","author":"Awad","year":"1993","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"e0148212","DOI":"10.1371\/journal.pone.0148212","article-title":"Antipsychotic dose mediates the association between polypharmacy and corrected QT interval","volume":"11","author":"Barbui","year":"2016","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub3","article-title":"Antipsychotic reduction and\/or cessation and antipsychotics as specific treatments for tardive dyskinesia","author":"Bergman","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD014384.pub2-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014383.pub2","article-title":"Antipsychotic polypharmacy reduction compared to polypharmacy continuation for people with schizophrenia","author":"Bighelli","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7108","key":"10.1002\/14651858.CD014384.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0187|cit187","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0188|cit188","first-page":"2125","article-title":"Employment and the associated impact on quality of life in people diagnosed with schizophrenia","volume":"11","author":"Bouwmans","year":"2015","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"7","key":"10.1002\/14651858.CD014384.pub2-BIB0189|cit189","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12888-018-1889-2","article-title":"Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia","volume":"18","author":"Caroff","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Buchanan","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-1781(97)03031-X","article-title":"The Maryland Psychiatric Research Center scale and the characterization of involuntary movements","volume":"70","author":"Cassady","year":"1997","journal-title":"Psychiatry Research"},{"issue":"8","key":"10.1002\/14651858.CD014384.pub2-BIB0193|cit193","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub3","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Ceraso","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"Journal of\u00a0Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0195|cit195","unstructured":"Covidence Veritas Health Innovation"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1192\/bjp.156.6.798","article-title":"Insight and psychosis","volume":"156","author":"David","year":"1990","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","article-title":"A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients","volume":"166","author":"Day","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0198|cit198","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0199|cit199","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0200|cit200","first-page":"13","article-title":"Symptom checklist-90 (SCL-90), an out-patient rating scale: preliminary report","volume":"9","author":"Deragotis","year":"1973","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0201|cit201","volume-title":"S3 Guideline for Schizophrenia. Abbreviated version","author":"DGPPN eV (ed) for the Guideline Group","year":"2019"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD014384.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD014384.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1-2","key":"10.1002\/14651858.CD014384.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0920-9964(01)00247-X","article-title":"Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia","volume":"56","author":"El Yazaji","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0211|cit211","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"9","key":"10.1002\/14651858.CD014384.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0213|cit213","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression \u2013 Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1017\/S0033291712000220","article-title":"Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study","volume":"42","author":"Harrow","year":"2012","journal-title":"Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archpsyc.1975.01760210077005","article-title":"Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia","volume":"32","author":"Hawk","year":"1975","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"issue":"1-02","key":"10.1002\/14651858.CD014384.pub2-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD014384.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0220|cit220","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0221|cit221","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-244X-11-28","article-title":"Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia","volume":"11","author":"Hill","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","article-title":"Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia","volume":"68","author":"Ho","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychological Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/schbul\/sbab017","article-title":"A method for tapering antipsychotic treatment that may minimize the risk of relapse","volume":"47","author":"Horowitz","year":"2021","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0228|cit228","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S2215-0366(21)00078-X","article-title":"Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"H\u00f8jlund","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0229|cit229","volume-title":"DIEPSS: A Second-Generation Rating Scale for Antipsychotic-Induced Extrapyramidal Symptoms: Drug-Induced Extrapyramidal Symptoms Scale","author":"Inada","year":"2009"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0230|cit230","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/npr2.12193","article-title":"Guideline for pharmacological therapy of schizophrenia","volume":"41","author":"Japanese Society of Neuropsychopharmacology","journal-title":"Neuropsychopharmacology Reports"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1185\/03007999909113374","article-title":"Patient satisfaction with, and acceptability of, atypical antipsychotics","volume":"15","author":"Kalali","year":"1999","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0233|cit233","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"9","key":"10.1002\/14651858.CD014384.pub2-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","article-title":"The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization","volume":"165","author":"Kern","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD014384.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.clinthera.2004.12.009","article-title":"Clinical review of a long-acting, injectable formulation of risperidone","volume":"26","author":"Knox","year":"2004","journal-title":"Clinical Therapy"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D 2 receptor occupancy for doses of 8 antipsychotics - a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"Journal of\u00a0Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0238|cit238","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/9781119536604.ch4","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2019"},{"issue":"11","key":"10.1002\/14651858.CD014384.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/jamapsychiatry.2014.2178","article-title":"A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia","volume":"72","author":"Lesh","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD014384.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0243|cit243","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub2","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014384.pub2-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophrenia Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD014384.pub2-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jamapsychiatry.2021.2130","article-title":"Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis","volume":"78","author":"Leucht","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD014384.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0920-9964(02)00335-3","article-title":"The InterSePT scale for suicidal thinking reliability and validity","volume":"63","author":"Lindenmayer","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"Suppl 44","key":"10.1002\/14651858.CD014384.pub2-BIB0248|cit248","first-page":"5","article-title":"Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)","volume":"55","author":"Lindstr\u00f6m","year":"2001","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0250|cit250","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40263-019-00682-8","article-title":"Achieving the lowest effective antipsychotic dose for patients with remitted psychosis: a proposed guided dose-reduction algorithm","volume":"34","author":"Liu","year":"2020","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1002\/14651858.CD014384.pub2-BIB0251|cit251","first-page":"5887","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiology Reviews"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"e0195687","DOI":"10.1371\/journal.pone.0195687","article-title":"Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses","volume":"13","author":"Moreno-K\u00fcstner","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Medical Care"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0256|cit256","first-page":"323","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0257|cit257","first-page":"133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","volume":"10 Suppl 3","author":"Naber","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD014384.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/08039488.2014.898790","article-title":"Is the PANSS cognitive scale measuring cognition?","volume":"68","author":"Nielsen","year":"2014","journal-title":"Nordic Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1008901320492","article-title":"A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation","volume":"9","author":"O'Carroll","year":"2000","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archpsyc.62.3.247","article-title":"The lifetime risk of suicide in schizophrenia: a re-examination","volume":"62","author":"Palmer","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.euroneuro.2014.01.014","article-title":"Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales","volume":"24","author":"Patel","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD014384.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/acps.12332","article-title":"Risk factors for suicide in schizophrenia: systematic review and clinical recommendations","volume":"130","author":"Popovic","year":"2014","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0266|cit266","unstructured":"Posner K Brent D Lucas C Gould M Stanley B Brown G Columbia-suicide severity rating scale (C-SSRS) cssrs.columbia.edu\/wp-content\/uploads\/C-SSRS_Pediatric-SLC_11.14.16.pdf"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0267|cit267","unstructured":"R: a language and environment for statistical computing R Foundation for Statistical Computing 2017"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1192\/bjp.bp.114.157685","article-title":"Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China","volume":"207","author":"Ran","year":"2015","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"Journal of Clinical and Experimental Neuropsychology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0270|cit270","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0271|cit271","unstructured":"Cochrane Review Group Risk of Bias 2 Starter Pack methods.cochrane.org\/file\/rob-2-starter-pack-cochrane-reviews.pdf"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/ebmental-2020-300151","article-title":"Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies","volume":"24","author":"Roberts","year":"2021","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0274|cit274","first-page":"57","article-title":"Comparison of paliperidone palmitate and second-generation oral antipsychotics in terms of medication adherence, side effects, and quality of life","volume":"39","author":"Sa\u011flam Aykut","year":"2019","journal-title":"Journal of\u00a0Clinical\u00a0Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/schbul\/sby095","article-title":"How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials","volume":"45","author":"Samara","year":"2019","journal-title":"Schizophrenia Bulletin"},{"issue":"2-3","key":"10.1002\/14651858.CD014384.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.schres.2009.05.032","article-title":"Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders","volume":"113","author":"Schennach-Wolff","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S2215-0366(19)30223-8","article-title":"Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis","volume":"6","author":"Schneider-Thoma","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0279|cit279","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from\u00a0training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1207\/s15327752jpa4703_14","article-title":"A shortened version of the Profile of Mood States","volume":"47","author":"Shacham","year":"1983","journal-title":"Journal of Personality Assessment"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S026418010000059X","article-title":"The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics","volume":"15","author":"Shepherd","year":"1989","journal-title":"Psychological Medicine Supplement"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0282|cit282","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0283|cit283","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0284|cit284","doi-asserted-by":"publisher","first-page":"sgaa061","DOI":"10.1093\/schizbullopen\/sgaa061","article-title":"Cochrane Schizophrenia Group\u2019s study-based register of randomized controlled trials: development and content analysis","volume":"1","author":"Shokraneh","year":"2020","journal-title":"Schizophrenia Bulletin Open"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0285|cit285","unstructured":"Shokraneh F Adams CE Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis Health Information and Libraries Journal 1 16 10.1111\/hir.12366"},{"issue":"7","key":"10.1002\/14651858.CD014384.pub2-BIB0286|cit286","first-page":"1041","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"Journal of\u00a0Clinical Psychiatry"},{"issue":"S212","key":"10.1002\/14651858.CD014384.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00496058","article-title":"A rating scale for tardive dyskinesia","volume":"64","author":"Simpson","year":"1979","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41537-018-0053-9","article-title":"Risk of weight gain for specific antipsychotic drugs: a meta-analysis","volume":"4","author":"Spertus","year":"2018","journal-title":"NPJ Schizophrenia"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0290|cit290","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD014384.pub2-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/archpsyc.1974.01760130021003","article-title":"The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia","volume":"31","author":"Strauss","year":"1974","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014384.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archpsyc.1977.01770140049005","article-title":"Prediction of outcome in schizophrenia: III. Five-yearn outcome and its predictors","volume":"34","author":"Strauss","year":"1977","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD014384.pub2-BIB0293|cit293","first-page":"323","article-title":"Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia","volume":"18","author":"Suzuki","year":"2003","journal-title":"International\u00a0Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.schres.2011.11.021","article-title":"Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms","volume":"134","author":"Takeuchi","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/eb-2015-102209","article-title":"Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2\/3 receptor occupancy following risperidone and olanzapine dose reduction","volume":"18","author":"Takeuchi","year":"2015","journal-title":"Evidence-Based Mental Health"},{"issue":"2-3","key":"10.1002\/14651858.CD014384.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.psychres.2005.05.006","article-title":"Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder","volume":"136","author":"Tandon","year":"2005","journal-title":"Psychiatry Research"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","article-title":"Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials","volume":"45","author":"Tani","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/acps.12913","article-title":"Mortality in schizophrenia: 30-year nationwide follow-up study","volume":"138","author":"Tanskanen","year":"2018","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol - a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group\u00a0","year":"1990","journal-title":"Health Policy"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0920-9964(99)00130-9","article-title":"Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses","volume":"42","author":"Thompson","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0301|cit301","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD014384.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"10 Pt 1","key":"10.1002\/14651858.CD014384.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.neubiorev.2012.09.006","article-title":"Confounders of excessive brain volume loss in schizophrenia","volume":"37","author":"Van Haren","year":"2013","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"3","key":"10.1002\/14651858.CD014384.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00004356-198809000-00001","article-title":"The Groningen Social Disabilities Schedule: development, relationship with ICIDH, and psychometric properties","volume":"11","author":"Wiersma","year":"1988","journal-title":"International Journal of Rehabilitation Research"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"i5396","DOI":"10.1136\/bmj.i5396","article-title":"80% of China's clinical trial data are fraudulent, investigation finds","volume":"355","author":"Woodhead","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014384.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD014384.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD014384.pub2-BIB0310|cit310","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014384","article-title":"Antipsychotic dose reduction compared to dose continuation for people with schizophrenia","author":"Bighelli","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:33:57Z","timestamp":1752672837000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014384.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":310,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014384.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]}}}